Alexion Pharmaceuticals, Inc.
NASDAQ: ALXN
$182.50
+$0.00 (+0.0%)
Closing Price on July 28, 2021
ALXN Articles
The short interest in biotech stocks is mixed, judging by the short interest changes between the September 14 and September 28 settlement dates. There were notable swings in shares sold short from...
Published:
Last Updated:
With a couple of exceptions, the short interest in biotech stocks is on the rise again, judging by the short interest changes from September 14 settlement date versus the August 31 settlement date....
Published:
The short interest in biotech stocks is generally falling, judging by the short interest changes from August 31 settlement date versus the August 15 settlement date. We have tracked the key short...
Published:
The short interest in biotech stocks is generally rising, judging by the short interest changes from August 15 settlement date versus the July 31 settlement date. We have tracked the key short...
Published:
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall Street research calls this Thursday. Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) Raised to Outperform as...
Published:
Last Updated:
For several years it has been the case that Amgen Inc. (NASDAQ: AMGN) was considered a biotech though it had at least some of the same problems of Big Pharma players like Pfizer Inc. (NYSE: PFE)...
Published:
Last Updated:
These are some of this Thursday’s top analyst upgrades, downgrades, and initiations seen from Wall Street research calls this morning. Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) named Bull of...
Published:
Last Updated:
Stock splits usually bring back memories of the old tech bubble and dot-com bubble. Fundamentally, nothing changes at the company other than that smaller investors get to invest in shares at a...
Published:
Last Updated:
These are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street research calls this Tuesday morning. A123 Systems, Inc. (NASDAQ: AONE) Raised to Buy at BofA/ML. AECOM...
Published:
Last Updated:
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) has trumped Valeant Pharmaceuticals International, Inc. (NYSE: VRX) after it agreed to acquire Cephalon Inc. (NASDAQ: CEPH) in a $6.8 billion...
Published:
These are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street research calls this Friday morning. Alcatel-Lucent (NYSE: ALU) Raised to Neutral at Nomura. Alexion...
Published:
Last Updated:
Biotech and emerging pharma both seem to have almost no friends today despite a large stock market rally. It may take a resolution of the Genzyme Corporation (NASDAQ: GENZ) merger, and a successful...
Published:
Last Updated:
These are this Thursday morning’s top analyst upgrades, downgrades and initiations seen from Wall Street research calls: Alexion Pharmaceuticals (NASDAQ: ALXN) Raised to Outperform at Oppenheimer....
Published:
Last Updated:
Updated throughout the day. Citigroup (C) may earn $20 billion in 2012 (FT) Macquarie Group, Australia’s largest investment bank, is on the hunt for more U.S. assets. (Bloomberg) Regulators have...
Published:
These are this Wednesday’s top 10 analyst upgrades, downgrades, and initiations seen in Wall Street research calls: Archer-Daniels Midland (NYSE: ADM) Raised to Buy at Citigroup. Alexion...
Published:
Last Updated: